Skip to main content
OpenTrials
Completed

NCT Number: NCT03083249

Gardasil Knowledge

Human papillomavirus (HPV) is the most common viral genital tract infection. The majority of women and men who are sexually active will be exposed to a strain or strains of the virus. While there are hundreds of viral strains, high risk strains are associated cervical and oral cancers. According to the Centers for Disease Control (CDC), between 2008 and 2012 there were 38,793 deaths attributed to HPV related cancers. Vaccinations were created in an attempt to prevent infection from the most common high risks strains of HPV. Gardasil/HPV-9 was created to help prevent HPV related cancers and warts. The HPV-9 vaccine includes protection from 7 strains of HPV associated with 74% of HPV related cancers. While Gardasil was approved and released in 2006, many men and women have not been vaccinated. A national immunization survey in 2011 of teens 13-17 years old noted that only 60% of girls and 40% of boys have received at least one vaccination in the series. While complete vaccination series is recommended, a recent study found that a single dose of Gardasil when compared to placebo created a higher level of serum antibodies in uninfected females.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HPV

Age range

18 year–26 year

Sex eligibility

Female

Study type

Observational

Primary location

St. Mary's Health Center

St Louis, Missouri, 63117, United States

About this study

All patients seen at a single clinic will be offered participation in the anonymous survey. The survey will ask a series of questions regarding basic demographics, sexual history, smoking status, and Gardasil vaccine knowledge. The survey will serve as evidence of the vaccine utility by highlighting patient risk factors for HPV and patient knowledge about the vaccine series.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients 18-26 will be offered participation

Exclusion criteria

  • Not meeting the inclusion criteria

Treatment and study plan

Gardasil

Other

None-data gathering only

Primary outcomes

  1. knowledge about HPV risk factors

    Time frame: 1 year

    The survey asks about Gardasil vaccine knowledge

Sponsors and collaborators

Lead sponsor

Sarah Hostetter, MD

Other

Registry information

Official study title

Gardasil Anonymous Survey

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Mar 17, 2017
Registry last updated
Jun 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.